ORUM (475830) - Total Liabilities
Based on the latest financial reports, ORUM (475830) has total liabilities worth ₩29.73 Billion KRW (≈ $20.15 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ORUM (475830) equity growth momentum to track the company's year-over-year net asset growth rate.
ORUM - Total Liabilities Trend (2022–2024)
This chart illustrates how ORUM's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of ORUM to measure how efficiently the company converts operating cash flow to free cash.
ORUM Competitors by Total Liabilities
The table below lists competitors of ORUM ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wag! Group Co.
NASDAQ:PET
|
USA | $32.41 Million |
|
Kavango Resources PLC
LSE:KAV
|
UK | GBX937.00K |
|
TUGA INNOVATIONS INC.
F:DQ5
|
Germany | €1.82 Million |
|
Crown LNG Holdings Limited Ordinary Shares
NASDAQ:CGBS
|
USA | $16.20 Million |
|
TUT Fitness Group Inc
V:GYM
|
Canada | CA$533.79K |
|
TTA Holdings Ltd
AU:TTA
|
Australia | AU$594.78K |
|
Tongaat
JSE:TON
|
South Africa | ZAC7.30 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down ORUM's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ORUM (475830) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.31 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ORUM's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ORUM (2022–2024)
The table below shows the annual total liabilities of ORUM from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩32.07 Billion ≈ $21.73 Million |
-85.29% |
| 2023-12-31 | ₩217.96 Billion ≈ $147.71 Million |
+46.54% |
| 2022-12-31 | ₩148.74 Billion ≈ $100.80 Million |
-- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, wh… Read more